Published in
American Association of Immunologists, ACS pharmacology & translational science, 11(5), p. 1156-1168, 2022
Links
Tools
Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors
Journal article published in 2022 by
Bárbara B. Sousa,
Cátia Rebelo de Almeida,
Ana F. Barahona,
Raquel Lopes,
Ana Martins-Logrado,
Marco Cavaco 
,
Vera Neves ,
Luís A. R. Carvalho,
Carlos Labão-Almeida,
Ana R. Coelho,
Marta Leal Bento,
Ricardo M. R. M. Lopes,
Bruno L. Oliveira,
Miguel A. R. B. Castanho ,
Peter Neumeister
and other authors.
,
Vera Neves ,
Luís A. R. Carvalho,
Carlos Labão-Almeida,
Ana R. Coelho,
Marta Leal Bento,
Ricardo M. R. M. Lopes,
Bruno L. Oliveira,
Miguel A. R. B. Castanho ,
Peter Neumeister
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 